Infliximab-related hepatitis: discussion of a case and review of the literature
- 27 January 2010
- journal article
- case report
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 5 (3) , 193-200
Abstract
Despite its rarity, infliximab-related hepatitis constitutes a cutting edge and challenging problem. In December 2004, a drug warning was issued by the Food and Drug Administration to alert healthcare professionals to the risk of hepatotoxicity in course of infliximab therapy. Subsequently, several reports of probable infliximab hepatitis have been published and interest is growing in trying to elucidate the impact of these events on clinical practice. After discussing our case report, the main characteristics of infliximab-mediated liver injury are analyzed, coupled with a review of the medical literature. Infliximab seems to provoke both immunomediated and a direct liver injury, but how this latter happens remains unclear. Moreover, infliximab immunomediated liver dysfunction resembles that of autoimmune hepatitis type I, with elevation of antinuclear, anti-smooth muscle, anti-double-strand DNA antibodies, and a clear preference for female sex. Finally, a flow chart is proposed with the purpose to help clinicians in the management of patients who develop signs of liver dysfunction during treatment with infliximab.Keywords
This publication has 30 references indexed in Scilit:
- Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanerceptClinical Rheumatology, 2009
- Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisisClinical and Experimental Dermatology, 2009
- Etanercept tolerance in a patient with previous infliximab-induced hepatitisClinical Rheumatology, 2008
- Tumor Necrosis Factor Inhibitors for Rheumatoid ArthritisNew England Journal of Medicine, 2006
- Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximabClinical Rheumatology, 2006
- Hepatitis: a rare, but important, complication of infliximab therapy for psoriasisClinical and Experimental Dermatology, 2006
- Serious liver disease induced by infliximabClinical Rheumatology, 2006
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: Comment on the article by Charles et alArthritis & Rheumatism, 2001
- International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitisJournal of Hepatology, 1999